Revolade Tablets Specified Drug-use Survey (Pediatric Aplastic Anemia Naive to Treatment With Anti-thymocyte Immunoglobulin, CETB115G1401)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 19 Jul 2024 Status changed from not yet recruiting to recruiting.
- 17 Jul 2024 Planned initiation date changed from 28 Jun 2024 to 31 Jul 2024.
- 24 Jun 2024 Planned End Date changed from 31 Oct 2028 to 28 Mar 2029.